Compare Stocks: PGEN, IBRX, RYTM, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$7.17 -3.8%	$7.70	$1.95 ▼ $12.43	$7.51B	0.03	9.53 million shs	9.32 million shs
MIRM Mirum Pharmaceuticals	$105.95 -5.9%	$110.06	$50.25 ▼ $130.00	$6.46B	0.52	608,944 shs	558,510 shs
PGEN Precigen	$6.27 +5.6%	$4.98	$1.63 ▼ $6.28	$2.24B	1.02	3.83 million shs	5.62 million shs
RYTM Rhythm Pharmaceuticals	$99.25 -6.1%	$100.57	$74.50 ▼ $122.20	$6.80B	1.92	611,047 shs	447,071 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	0.00%	+0.99%	-24.05%	+0.84%	+180.08%
MIRM Mirum Pharmaceuticals	0.00%	-6.26%	-15.64%	+9.76%	+107.26%
PGEN Precigen	0.00%	+16.11%	+11.17%	+53.68%	+262.43%
RYTM Rhythm Pharmaceuticals	0.00%	-2.79%	-13.07%	+21.32%	+17.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$7.17 -3.8%	$7.70	$1.95 ▼ $12.43	$7.51B	0.03	9.53 million shs	9.32 million shs
MIRM Mirum Pharmaceuticals	$105.95 -5.9%	$110.06	$50.25 ▼ $130.00	$6.46B	0.52	608,944 shs	558,510 shs
PGEN Precigen	$6.27 +5.6%	$4.98	$1.63 ▼ $6.28	$2.24B	1.02	3.83 million shs	5.62 million shs
RYTM Rhythm Pharmaceuticals	$99.25 -6.1%	$100.57	$74.50 ▼ $122.20	$6.80B	1.92	611,047 shs	447,071 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	0.00%	+0.99%	-24.05%	+0.84%	+180.08%
MIRM Mirum Pharmaceuticals	0.00%	-6.26%	-15.64%	+9.76%	+107.26%
PGEN Precigen	0.00%	+16.11%	+11.17%	+53.68%	+262.43%
RYTM Rhythm Pharmaceuticals	0.00%	-2.79%	-13.07%	+21.32%	+17.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	98.05% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$143.40	35.35% Upside
PGEN Precigen	2.33	Hold	$12.50	99.36% Upside
RYTM Rhythm Pharmaceuticals	2.78	Moderate Buy	$138.73	39.78% Upside

Current Analyst Ratings Breakdown

Latest PGEN, IBRX, RYTM, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/27/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$145.00
7/17/2026	PGEN Precigen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RYTM Rhythm Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	IBRX ImmunityBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$137.00 ➝ $141.00
7/7/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$142.00 ➝ $148.00
7/2/2026	MIRM Mirum Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$115.00 ➝ $125.00
6/23/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/17/2026	RYTM Rhythm Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/16/2026	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$143.00 ➝ $151.00
6/15/2026	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$133.00

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBRX ImmunityBio	$113.29M	66.29	N/A	N/A	($0.51) per share	-14.06
MIRM Mirum Pharmaceuticals	$521.31M	12.39	$0.05 per share	2,078.30	$6.12 per share	17.31
PGEN Precigen	$9.68M	230.92	N/A	N/A	$0.06 per share	104.50
RYTM Rhythm Pharmaceuticals	$189.76M	35.84	N/A	N/A	$2.08 per share	47.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBRX ImmunityBio	-$351.40M	-$0.85	N/A	N/A	N/A	-606.15%	N/A	-59.53%	8/4/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$13.61	N/A	815.00	N/A	-140.24%	-11.28%	-3.84%	8/5/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.18	N/A	25.08	N/A	-646.99%	717.50%	58.48%	8/4/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.13	N/A	N/A	N/A	-93.33%	-203.25%	-44.99%	8/4/2026 (Estimated)

Latest PGEN, IBRX, RYTM, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7279	N/A	N/A	N/A	$166.04 million	N/A
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	N/A	N/A	N/A	$49.70 million	N/A
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	N/A	N/A	N/A	$27.98 million	N/A
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	N/A	N/A	N/A	$67.66 million	N/A
5/13/2026	Q1 2026	PGEN Precigen	-$0.03	-$0.02	+$0.01	-$0.02	$20.81 million	$23.25 million
5/7/2026	Q1 2026	IBRX ImmunityBio	-$0.08	-$0.62	-$0.54	-$0.62	$43.07 million	$44.21 million
5/6/2026	Q1 2026	MIRM Mirum Pharmaceuticals	-$0.75	-$13.43	-$12.68	-$13.43	$148.21 million	$159.88 million
5/5/2026	Q1 2026	RYTM Rhythm Pharmaceuticals	-$0.86	-$0.83	+$0.03	-$0.83	$55.78 million	$60.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBRX ImmunityBio	N/A	6.67	6.66
MIRM Mirum Pharmaceuticals	1.28	2.09	1.99
PGEN Precigen	4.62	4.82	4.12
RYTM Rhythm Pharmaceuticals	N/A	4.17	3.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBRX ImmunityBio	8.58%
MIRM Mirum Pharmaceuticals	N/A
PGEN Precigen	33.51%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
IBRX ImmunityBio	66.10%
MIRM Mirum Pharmaceuticals	8.32%
PGEN Precigen	41.40%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBRX ImmunityBio	590	1.05 billion	355.05 million	Optionable
MIRM Mirum Pharmaceuticals	140	60.98 million	55.91 million	Optionable
PGEN Precigen	190	356.51 million	208.92 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable

PGEN, IBRX, RYTM, and MIRM Headlines

Recent News About These Companies

Perceptive Advisors LLC Has $206.45 Million Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM

August 2 at 6:15 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Janus Henderson Group PLC

August 1 at 6:08 AM | marketbeat.com

Rhythm Pharmaceuticals Inc.

July 30 at 5:34 PM | marketwatch.com

Renaissance Technologies LLC Lowers Stake in Rhythm Pharmaceuticals, Inc. $RYTM

July 30 at 5:04 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Position Raised by ADAR1 Capital Management LLC

July 29, 2026 | marketbeat.com

JPMorgan Chase & Co. Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)

July 29, 2026 | americanbankingnews.com

Could Anticipated Q2 Earnings Beat Amid Weaker Profitability Reframe Rhythm Pharmaceuticals’ Growth Story (RYTM)?

July 28, 2026 | uk.finance.yahoo.com

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

July 28, 2026 | zacks.com

Rhythm Pharmaceuticals (RYTM) Projected to Announce Earnings on Tuesday

July 28, 2026 | marketbeat.com

Exome Asset Management LLC Takes $3.53 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM

July 28, 2026 | marketbeat.com

Hsbc Holdings PLC Invests $1.23 Million in Rhythm Pharmaceuticals, Inc. $RYTM

July 28, 2026 | marketbeat.com

Castleark Management LLC Sells 12,200 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

July 28, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at JPMorgan Chase & Co.

July 27, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by Orbimed Advisors LLC

July 27, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by SummitTX Capital L.P.

July 27, 2026 | marketbeat.com

First Light Asset Management LLC Sells 208,663 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

July 27, 2026 | marketbeat.com

Granahan Investment Management LLC Increases Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM

July 25, 2026 | marketbeat.com

Siren L.L.C. Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM

July 24, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

July 21, 2026 | prnewswire.com

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 21, 2026 | markets.businessinsider.com

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

July 21, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, IBRX, RYTM, and MIRM Company Descriptions

ImmunityBio NASDAQ:IBRX

$7.17 -0.28 (-3.76%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$7.20 +0.03 (+0.42%)

As of 07/31/2026 07:59 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$105.95 -6.64 (-5.90%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$104.90 -1.06 (-1.00%)

As of 07/31/2026 07:34 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Precigen NASDAQ:PGEN

$6.27 +0.33 (+5.56%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$6.22 -0.05 (-0.80%)

As of 07/31/2026 07:59 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Rhythm Pharmaceuticals NASDAQ:RYTM

$99.25 -6.49 (-6.14%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$99.78 +0.53 (+0.53%)

As of 07/31/2026 07:34 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PGEN, IBRX, RYTM, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PGEN, IBRX, RYTM, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PGEN, IBRX, RYTM, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, IBRX, RYTM, and MIRM Company Descriptions

ImmunityBio NASDAQ:IBRX

Mirum Pharmaceuticals NASDAQ:MIRM

Precigen NASDAQ:PGEN

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PGEN, IBRX, RYTM, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PGEN, IBRX, RYTM, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PGEN, IBRX, RYTM, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, IBRX, RYTM, and MIRM Company Descriptions

ImmunityBio NASDAQ:IBRX

Mirum Pharmaceuticals NASDAQ:MIRM

Precigen NASDAQ:PGEN

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools